First human doses given in early drug safety trial
NCT ID NCT07232121
Summary
This is the first study in humans for a new drug called DF5112. Its main purpose is to check if the drug is safe and how the body handles it. The study will enroll 64 healthy adults who will receive either the drug or a placebo. Researchers will monitor participants closely for side effects and track how the drug moves through the body over several weeks.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEALTHY ADULT MALE are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Scientia Clinical Research Ltd
RECRUITINGSydney, New South Wales, 2031, Australia
Contact
Conditions
Explore the condition pages connected to this study.